Rallybio sets 1-for-2 reverse stock split ahead of Avenzo merger
Rallybio will combine shares 1-for-2 effective November 20, 2026, a step tied to its planned merger with Avenzo Therapeutics and name change to Avenzo Therapeutics, Inc.
SEC filing
Latest
3 stories
Today
Friday, November 6
Rallybio and Avenzo postpone merger closing past November 6, 2026 target
Listing approvals remain outstanding, and Rallybio says a related cash distribution's payment and ex-dividend dates may also be delayed.
SEC filing
Wednesday, November 4
Rallybio stockholders approve Avenzo merger, name change, and reverse split
At a November 4, 2026 annual meeting, Rallybio shareholders cleared all eight proposals tied to the Avenzo Therapeutics merger, which the company expects to close November 6, 2026.
SEC filing